Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17357501 | 1.00 | L3MBTL1 (0.61) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL2416799 | 0.84 | ATM (0.59) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL8975800 | 0.84 | L3MBTL1 (0.59) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL23886612 | 0.84 | L3MBTL1 (0.50) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL11232929 | 0.84 | L3MBTL1 (0.50) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL23886615 | 0.84 | L3MBTL1 (0.50) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL1706949 | 0.83 | ATM (0.58) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL1703642 | 0.83 | ATM (0.58) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL7836922 | 0.83 | ATM (0.49) | L3MBTL1ATMSRCCYP2D6LMNA | |
| SCHEMBL16682784 | 0.83 | SRC (0.46) | L3MBTL1ATMSRCCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102977098-B | Aryl-substituted indolizine derivative and preparation method and applications thereof | UNIV SHAOXING | 2015-04-01 | — | — | CN | claimed |
| CN-102977098-A | Aryl-substituted indolizine derivative and preparation method and applications thereof | UNIV SHAOXING | 2013-03-20 | — | — | CN | claimed |
| CN-108368099-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-110330420-B | Process for preparing acids with different substituents | 湖南大学 | 2020-07-10 | — | — | CN | disclosed |
| CN-110330420-A | The preparation method of the acid of different substituents | 湖南大学 | 2019-10-15 | — | — | CN | disclosed |
| EP-3390399-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| CN-107923120-A | Composition for reducing malodour and use thereof | 阿吉莱克斯香料和香水公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2017102006-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| EP-2897960-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| CN-102977098-B | Aryl-substituted indolizine derivative and preparation method and applications thereof | UNIV SHAOXING | 2015-04-01 | — | — | CN | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| CN-1927809-A | Preparation method of t-butylphenyl acetic acid | UNIV SHANGHAI (CN) | 2007-03-14 | — | — | CN | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0253501-A2 | N-disubstituted cycloalkylmethyl amines useful as fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | L3MBTL1 4353/4885ATM 614/4885SRC 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.